Beranda › Limfoma Sel B › Michigan
Uji klinis Limfoma Sel B di Michigan
7 studi untuk Limfoma Sel B mencari peserta di lokasi di Michigan.
Kota di Michigan
Teks studi resmi (Bahasa Inggris)
A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)
- University of Michigan, Ann Arbor
- The Cancer and Hematology Centers, Grand Rapids
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT06742996A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
- University of Michigan Comprehensive Cancer Center, Ann Arbor
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07101328A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma.
- Clinical Trial Site, Detroit
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Sep 2026 · NCT06393738Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Corewell Health, Grand Rapids
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Agu 2026 · NCT05826535Pomalidomide After CAR T-cell Therapy for the Treatment of Relapsed or Refractory CD19+ B-cell Leukemia or Lymphoma
- University of Michigan Rogel Cancer Center, Ann Arbor
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 16 Jul 2026 · NCT07532525DALY II USA/ MB-CART2019.1 for DLBCL
- University of Michigan, Ann Arbor
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT04792489Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies
- C.S. Mott Children's Hospital, Ann Arbor
Menerima pesertaFase 1
Usia 1 hingga 21 · Semua jenis kelamin · Diperbarui 6 Des 2024 · NCT05476770Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.